Amgen Reports Seven-Year ASPIRE Data for Kyprolis in Multiple Myeloma

Amgen today presented seven-year follow-up data from the Phase 3 ASPIRE trial evaluating Kyprolis (carfilzomib) plus lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. The data showed that the overall survival benefit of KRd was maintained at seven years, with 33% of patients in the KRd arm alive at seven years compared to 27% in the Rd arm.